Uptravi Found to Reduce Risk, by Half, of PAH Disease Progression

Uptravi Found to Reduce Risk, by Half, of PAH Disease Progression

304693

Uptravi Found to Reduce Risk, by Half, of PAH Disease Progression

Early treatment with Janssen’s Uptravi (selexipag) can halve the risk of disease progression for people with pulmonary arterial hypertension (PAH), a new analysis found. The results showed patients treated with Uptravi within six months of PAH diagnosis saw their risk of disease progression reduced by 52% compared with a placebo, according to Janssen. “This analysis reinforces the role of selexipag [Uptravi] in early treatment escalation to help reduce the risk of disease progression and improve…

You must be logged in to read/download the full post.